Form 4: Bristol-Myers Squibb Director Acquires Deferred Share Units

Director Michael R. McMullen acquired 552.511 deferred share units of Bristol-Myers Squibb on December 31, 2024.

Summary

• Michael R. McMullen, a director at Bristol-Myers Squibb, acquired 552.511 deferred share units on December 31, 2024.
• These deferred share units will convert into common stock upon settlement, which occurs when Mr. McMullen ceases to be a director or at a previously specified future date.
• The price per unit was $56.56.
• Following the transaction, Mr. McMullen beneficially owns 4,220.713 deferred share units, which includes deferred compensation and reinvested dividends.

Sentiment

Score: 7

Explanation: The document reflects a routine transaction related to director compensation, which is generally viewed as neutral to slightly positive as it aligns director interests with shareholders. There is no indication of any negative sentiment.

Positives

• The acquisition of deferred share units by a director signals confidence in the company's future performance.

Future Outlook

The deferred share units will convert to common stock upon settlement, which will occur when the director ceases to be a director or at a previously specified future date.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It reflects the compensation structure for non-employee directors.

Comparison to Industry Standards

• The use of deferred share units as part of director compensation is a common practice among large publicly traded companies, including pharmaceutical companies like Pfizer (PFE) and Merck (MRK).
• These companies often use a mix of cash and equity-based compensation to align the interests of directors with those of shareholders.
• The specific terms of the deferred share units, such as the vesting schedule and settlement conditions, are typical for director compensation plans.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns the director's interests with the company's long-term performance.

Key Dates

Keywords

Deferred Share Units, Director, Insider Trading, SEC Form 4, Bristol-Myers Squibb, BMY, Equity Securities